news
Quintiles and Biogen Idec announce comprehensive clinical development partnership
24 April 2014 | By Biogen Idec
Quintiles and Biogen Idec have entered into a five-year strategic clinical development agreement...
List view / Grid view
Quintiles Limited
article
Roundtable: The future direction for clinical trials
Sally Burtles, Stephen Freestone and Eddie Caffrey discuss the future direction for clinical trials, covering the main challenges faced in the current application of Phase I clinical trials, changes the industry be implementing in order to further improve the efficiency of early clinical trials and how the Regulatory bodies’ guidance…
article
Taking clinical trials into the future
27 March 2007 | By EPR
Q1: Please outline the general process of Phase I clinical trials. Burnand: Phase I is the screening for safety process and it’s the first time that a product is given to a human being. The aim at this stage is to demonstrate that the product isn’t dangerous. The data will…
article
Integration is key
24 March 2006 | By E. Allen, T. Mant, C. Vose: Guy’s Drug Research Unit, Quintiles Limited
Drug development has become more complex and significantly more expensive. There has been an estimated 55% increase in the critical path development costs since the year 20001. More than 50% of these costs are incurred in later phase development (Phase IIb and III studies).
